Index - 68 - 69/70/71 - 72/73 - 74/75 - 76/77 - 78 - 79 - 80
TABLE 2: CLASSIFICATION OF AND INTERVENTIONS FOR HCV/HIV-CO-INFECTED NON-RESPONDERS/ RELAPSERS TO PRIOR INTERFERON-BASED THERAPIES
Category Subgroup Suggested Intervention
Suboptimal treatment

Suboptimal schedule

  • Interferon (monotherapy or with ribavirin)
  • Low ribavirin dose
  • Short length of therapy
 Re-treatment using combination therapy with Peg-INF plus weight-based ribavirin dosing
Limiting toxicities & poor adherence Optimal support (SSRI, paracetamol/ NSAID, adherence support, use of hematopoietic growth factors a)
Optimal treatment with virological failure Relapse (HCV-RNA negative at the end of treatment) Re-treatment using combination therapy with Peg-INF plus weight-based ribavirin dosing (consider longer treatment duration)
Non Response (no HCV-RNA negativization during treatment) Wait until new antivirals become available either through clinical trials or are licensed.
a) Data on the use of hematopoietic growth factors in HIV/HCV co-infection so far is limited to an improvement in quality of life but not antiviral efficacy; treatment with growth factors is currently mostly off-label in Europe.